Important Deadline for Nektar Therapeutics Investors Approaches for Securities Class Action

Nektar Therapeutics Investors: Important Class Action Deadline Approaching

Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, has issued a reminder to investors of Nektar Therapeutics, Inc. (NASDAQ: NKTR) about an upcoming deadline related to a securities class action. This important legal notice pertains to investors who bought or acquired Nektar securities between February 26, 2025, and December 15, 2025. The deadline to file for lead plaintiff in this federal class action is May 5, 2026.

Background of the Case

The allegations against Nektar Therapeutics involve claims that the company and its executives might have breached federal securities laws. Specifically, the complaint accuses them of making misleading public statements and of failing to disclose critical issues regarding the REZOLVE-AA clinical trial. According to the allegations, enrollment for this trial did not adhere to the required protocols, which could have negatively affected the trial results.

The REZOLVE-AA trial was intended to assess an investigational drug, rezpegaldesleukin, a first-of-its-kind IL-2 pathway agonist. However, revelations emerged on December 16, 2025, when Nektar reported that the trial's results lacked statistical significance due to the inclusion of four ineligible patients. Following this disclosure, the company's stock experienced a significant drop, falling by $4.14 per share, about 7.77%, indicating investor concern and disappointment.

Investor Actions and Legal Rights

Investors who believe they have suffered losses due to these developments are strongly encouraged to reach out to Faruqi & Faruqi's Senior Partner, James (Josh) Wilson, at 877-247-4292 or 212-983-9330. This outreach provides an opportunity to discuss legal options in detail. Investors can also visit the law firm’s dedicated website for comprehensive information about the Nektar Therapeutics class action at www.faruqilaw.com/NKTR.

Moreover, it is crucial for investors to understand the process of becoming a lead plaintiff, which involves being the investor with the largest financial interest in the case and being representative of the interests of the class. Any member of the potential class can apply to serve as lead plaintiff through their chosen legal counsel.

Nektar's Commitment to Transparency

Faruqi & Faruqi insists on the importance of transparency and accountability in the corporate arena, particularly in relation to the health and pharmaceutical sectors. Their investigations serve to protect the rights of investors and hold companies accountable for their disclosures and operations.

The firm has a longstanding history, recovering hundreds of millions of dollars for investors since its establishment in 1995 and operates with offices across several states, including New York, Pennsylvania, California, and Georgia.

Conclusion

As the May 5 deadline approaches, investors in Nektar Therapeutics are advised to thoroughly assess their positions and consider contacting the law firm to explore their options for legal redress. The results of this case may significantly impact both Nektar’s future and the financial outcome for its investors. Stay informed and proactive in protecting your investment rights as developments unfold in this situation.